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We assessed the impact of five serologic tests on the link between Chlamydia pneumoniae and abdominal aortic
aneurysms (AAA). The results of the tests were inconsistent. Agreement among the five tests was generally poor.
Detection of the link between C. pneumoniae and AAA depends on the serologic methodology chosen.
Seroepidemiologic studies that investigated the link between
Chlamydia pneumoniae and vascular diseases have reported
inconsistent results, ranging from a strong link to no link at all
(3). This discrepancy might be due to methodological factors
(15). Two recent studies have demonstrated that the detection
of a link between C. pneumoniae and coronary artery disease
depends on the choice of serologic methods (6, 15). The sero-
logic link between C. pneumoniae and vascular diseases has
been assessed by microimmunofluorescence tests (MIF) and
enzyme-linked immunosorbent assays (ELISA). However,
these serologic tests lack sufficient reliability and standardiza-
tion (4). A poor agreement among the results of these tests has
been reported (6, 13, 15).
In this case-control study, we investigated whether the
choice of serologic tests influences the detection of a link
between C. pneumoniae and abdominal aortic aneurysms
(AAA). Moreover, we evaluated the agreement among the
results of these tests.
The study population used was previously described (9).
Patients with AAA and healthy controls were included and
matched by age and sex. Serum samples were tested for the
presence of C. pneumoniae immunoglobulin G (IgG) antibod-
ies by five serologic tests, i.e., the Chlamydia MIF IgG (MRL
Diagnostics, Cypress, Calif.), the Chlamydia IgG SeroFIA
(Savyon Diagnostics Ltd., Ashdod, Israel; Savyon MIF), the
Chlamydia IgG rELISA (Medac Diagnostica, Hamburg, Ger-
many), the SeroCP IgG (Savyon Diagnostics Ltd.; Savyon
ELISA), and the Elegance C. pneumoniae IgG ELISA (Bio-
clone, Marrickville, Australia).
The MRL MIF uses, as the antigen, purified C. pneumoniae
(strain TW 183) elementary bodies (EB) diluted in 3% yolk sac
to add contrast to the background. According to the manufac-
turer’s product information, the EB are purified by removing
the genus-specific lipopolysaccharide (LPS). The Savyon MIF
and the Savyon ELISA also use purified C. pneumoniae (strain
TW 183) EB as the antigen. The Medac rELISA uses a re-
combinant LPS fragment as the antigen. For the Bioclone
ELISA, purified C. pneumoniae outer membrane protein com-
plexes are used as the antigen. All tests were performed and
interpreted in a blinded fashion by the same technician, ac-
cording to the manufacturers’ instructions.
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TABLE 1. Baseline characteristics of patients with AAA and
control subjectsa
Characteristic No. ofpatients
No. of control
subjects P value
Age (yr) (range) 69 (45–85) 67 (44–83) NSc
Male/female 81/7 81/7 NS
Aneurysm
Under control 35
Operated 53
Elective 40
Symptomatic 7
Ruptured 6
Family history of aneurysm 16 9 NS
History
Myocardial infarction 26 9 0.01
Cerebrovascular disease 9 4 NS
Pulmonary embolism 2 3 NS
Chronic obstructive
pulmonary disease
24 13 NS
Peripheral vascular disease 19 4 0.01
Diabetes mellitus 6 4 NS
Smoking
Pack-yr of cigarette
smokingb (SD)
34 (33) 23 (22) 0.01
Medication
Antihypertensive drugs 48 28 0.01
Cholesterol-lowering drugs 28 8 0.001
Nonsteroidal anti-
inflammatory drugs
37 17 0.01
Mean systolic blood pressure
(mm Hg) (SEM)
159 (2.4) 158 (2.6) NS
Mean diastolic blood pressure
(mm Hg) (SEM)
85 (1.2) 87 (1.2) NS
Mean cholesterol
(mmol/liter SEM)
5.7 (1.13) 5.7 (0.10) NS
a Patients (n  88) and controls (n  88) were matched by age and sex.
b A pack-year was defined as smoking 20 cigarettes/day for 1 year.
c NS, not significant.
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We used odds ratios and a 95% confidence interval for
estimating the relative risk. Kappa () values were used to
assess the agreement among the tests. The following guidelines
were used in the interpretation of : if  was 0.2, agreement
was poor; if  was 0.21 to 0.4, agreement was fair; if  was 0.41
to 0.6, agreement was moderate; if  was 0.61 to 0.8, agreement
was good; and if  was 0.81 to 1.0, agreement was very good
(1). P values of 0.05 were considered statistically significant.
The study population included 88 patients with AAA and 88
healthy controls. The characteristics of the study population
are shown in Table 1. The results of the five tests were incon-
sistent (Table 2). In the patient group, seropositivity rates
varied from 52% (46 of 88 patients) with the Medac rELISA to
97% (85 of 88) with the MRL MIF. In the healthy controls, a
similar variation was found: 55% (48 of 88 controls) were
positive with the Medac rELISA compared to 97% (85 of 88)
with the Bioclone ELISA.
The MRL MIF was the only test that demonstrated a sig-
nificant link between C. pneumoniae and AAA. The other four
tests failed to demonstrate any link. However, the MRL MIF
also failed to demonstrate a link when higher IgG titers were
used as cutoffs. Although the results of the two MIF used in
our study were read by the same technician, there was poor
agreement between the two tests. This implies that in addition
to the subjective reading of MIF results, other factors may
contribute to the disagreement among results of C. pneu-
moniae serologic tests. The test procedure, the type of antigen,
the antigen’s purity, and the concentration of the antigen may
also account for poor agreement among the results of these
serologic tests (5). The link between low titers of C. pneu-
moniae IgG and AAA, demonstrated by the MRL MIF, might
be the result of a cross-reaction to the antigen used in the test
from sources other than C. pneumoniae (8). These sources,
either infectious or noninfectious, might be associated with
AAA and confound the association between C. pneumoniae
and AAA.
The agreement among the results obtained by the five sero-
logic tests was generally poor (Table 3). Inter- and intralabo-
ratory variations and a poor agreement among results of sero-
logic tests of C. pneumoniae have also been demonstrated by
others (6, 13, 15). Ranges of agreement from 59 to 90% have
been reported (13, 15). Hoymans et al. (6) found poor agree-
ment between results of the MIF and the Medac rELISA, but
three other ELISA showed moderate to good agreement in
results with the MIF (6).
There is evidence that C. pneumoniae serologic tests are less
specific than previously realized (5, 8, 11). Cross-reactivity be-
tween C. pneumoniae and Chlamydia species in the MIF has
been demonstrated (8, 11). This is probably due to a lack of
LPS removal from the EB during antigen preparation (11). It
is also possible that Chlamydia-like microorganisms, Bordetella
pertussis and parvovirus, cause serologic antigenic cross-reac-
tivity with C. pneumoniae (6, 7, 10, 12, 14).
Our results support the findings of recent studies which have
shown that methodology has an important impact on whether
a link is found between C. pneumoniae and vascular diseases
(6, 15). This indicates that methodological factors are partly
responsible for the conflicting results in the literature concern-
ing the role of C. pneumoniae in the development of vascular
diseases (2, 3).
This study shows that the detection of a serologic link be-
tween C. pneumoniae and AAA depends on which test is used
TABLE 2. Association between C. pneumoniae seropositivity and
AAA according to five different testsa
Test IgG titer or indexvalue
No. of
AAA
patients
No. of
controls
Odds ratio
(95% CI)b
MRL MIF IgG 1:16 85 71 6.8 (2.0–24.1)
IgG  1:512 24 21 1.2 (0.6–1.8)
Savyon MIF IgG 1:64 79 79 1.0 (0.4–2.7)
IgG  1:512 21 20 0.9 (0.5–1.8)
Medac rELISA IgG 1:100 46 48 0.9 (0.5–1.7)
IgG  1:400 23 18 1.4 (0.7–2.8)
Savyon ELISAc Index  1.10 67 71 0.8 (0.4–1.6)
Bioclone ELISAd Index  1.10 84 85 0.7 (0.2–3.4)
Index  3.0 20 16 1.3 (0.6–2.8)
a Eighty-eight patients and 88 controls were tested.
b CI, confidence interval.
c For the Savyon ELISA, high titers were not found.
d According to test kit instructions, an index value of  3 corresponds to an
IgG titer of 1:512.
TABLE 3. Agreement of  values between the serological results of the five different tests for the patient group and the healthy controls
Group and test IgG titer or indexvalue
 valuea
Savyon
MIF
Medac
rELISA
Savyon
ELISA
Bioclone
ELISAb
Patients
MRL MIF IgG  1:16 0.12 0.02 0.14 0.55
Savyon MIF IgG  1:64 0.12 0.45 0.42
Medac rELISA IgG 1:100 0.09 0.05
Savyon ELISA Index 1.10 0.26
Controls
MRL MIF IgG  1:16 0.11 0.06 0.12 0.25
Savyon MIF IgG  1:64 0.09 0.55 0.47
Medac rELISA IgG 1:100 0.15 0.08
Savyon ELISA Index 1.10 0.25
a  expresses the agreement between the tests regarding nominal scale variables (positive and negative results).
b The Bioclone ELISA had an index value of 1.10.
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to measure C. pneumoniae antibodies. Further studies should
focus on optimizing and standardizing C. pneumoniae serologic
methods.
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